FDA's September Warning Letter Brands Empower Pharmacy's GLP-1 Add-Ons ‘Pretextual’
TL;DR: FDA's 18 Sept 2026 letter calls Empower Pharmacy's added-vitamin GLP-1 blends “pretextual” copies of approved drugs.
What Did the FDA Say to Empower Pharmacy?
On 18 September 2026, the US Food and Drug Administration issued a warning letter to Empower Clinic Services, LLC, doing business as Empower Pharmacy, a large Houston-based compounding pharmacy.[1] The letter raises two separate categories of problem. First, FDA investigators found sterile products at the facility were “prepared, packed, or held under insanitary conditions” that could result in drugs “contaminated with filth or rendered injurious to health,” alongside cited gaps in equipment maintenance, microbial-contamination controls, quality-unit oversight, environmental monitoring, and written production records.[2] Trade press notes this is the fourth warning letter Empower has received in recent years over facility conditions, following an earlier letter dated April 2025.[3]
Second — and the more novel part of the letter for the wider compounding industry — FDA alleges that Empower's compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin formulations are essentially copies of FDA-approved commercial products, and that the volume in which they were produced suggests the added vitamin is a pretextual difference rather than a genuine, patient-specific one.[1] Legal commentary published in the days afterward describes this as apparently the first time FDA has used the specific word “pretextual” in a warning letter addressing GLP-1 co-formulations.[4]
Why Does Adding a Vitamin Matter Under Section 503A?
Section 503A of the Federal Food, Drug and Cosmetic Act exempts qualifying compounded human drugs from FDA's premarket-approval and manufacturing-practice requirements — but only if the pharmacy meets several statutory conditions, including a restriction against regularly compounding drugs that are essentially copies of a commercially available, FDA-approved product.[1] One recognised exception is a prescriber's documented determination that the compounded version produces a clinically significant difference for a named patient — historically, adding a low-cost ingredient such as a B-vitamin has been treated by parts of the industry as one way to establish that difference.
What the paperwork was supposed to show
A prescriber determines, for an individual patient, that a specific compounded formulation offers a meaningful clinical advantage over the approved commercial drug — not simply that it is available or cheaper.
What FDA says it actually found
Prescriptions lacking any individualised significant-difference determination; other records repeating near-identical significant-difference language across large numbers of patients, which FDA suggested may have been pre-generated text for a prescriber to select rather than an individual clinical judgment; and production and dispensing volumes the agency characterised as inconsistent with genuinely patient-specific compounding.[1]
Read together, FDA's position is that the paperwork process, not just the chemistry, failed to establish a real difference — which is what let the agency call the vitamin addition pretextual rather than accept it as a qualifying basis for the 503A exemption.
Which Products and Findings Were Named?
| Finding category | What FDA cited |
|---|---|
| Facility sterility / cGMP | Insanitary conditions risking contamination “with filth”; gaps in equipment, contamination control, quality oversight, environmental monitoring, production records |
| Co-formulation named | Tirzepatide with niacinamide |
| Co-formulation named | Semaglutide with cyanocobalamin |
| 503A statutory issue | Alleged failure to meet conditions for the compounding exemption; products alleged to be “essentially copies” of approved drugs |
| Evidence cited for pretextual finding | Missing or boilerplate significant-difference documentation; high compounding/dispensing volume |
Table for research reference only; see the FDA's published letter for full statutory and factual detail.[1]
How Does This Fit the FDA's Wider 2026 Compounding Crackdown?
This letter lands on top of a year of escalating FDA activity specifically targeting compounded tirzepatide and semaglutide. We covered the agency's move to exclude both compounds from the 503B bulk-substances list in July, and what followed once that comment period closed in August. Independent of the bulks-list question, a JAMA secret-shopper study we covered separately found compounded semaglutide and tirzepatide remained widely available from online sellers well after enforcement began.
Two enforcement tracks, one target. The Empower letter runs alongside a distinct track of FDA action against unlicensed websites marketing peptides as unapproved drugs — including the five online sellers cited on 1 September for retatrutide, tirzepatide and tesamorelin marketing. Empower is a licensed 503A pharmacy dispensing to patients under prescription; the September sellers were unlicensed websites. Both tracks target the same underlying compounds, through different statutory routes.
What Do Legal Commentators Say It Signals?
Legal analyses published in the days after the letter argue its significance extends well past Empower itself. One 24 September 2026 commentary frames it as putting the entire industry practice of pairing a GLP-1 with a token vitamin on notice: if production volume and documentation look mass-market rather than individualised, FDA is now on record treating that as evidence the added ingredient is pretextual, not a genuine 503A-qualifying difference.[4] A separate law-firm analysis frames the letter as a template for how FDA may approach other 503A pharmacies using similar co-formulation strategies, while trade coverage has also noted the letter raises fresh questions about how far a “medical necessity” exception can stretch for mass-marketed compounded GLP-1s.[5][6]
As of publication, Empower had not issued a detailed public response, and FDA had not announced further action such as seizure or injunction. Warning letters of this kind typically give the recipient a limited window to describe corrective steps before the agency considers escalation.
Does This Affect UK Research-Reagent Supply?
No. Section 503A is a US statutory framework governing licensed pharmacies that compound FDA-approved drugs for named patients under prescription — it has no UK equivalent and no bearing on the UK's Human Medicines Regulations 2012, under which research reagents supplied strictly for in vitro laboratory use are assessed; see our guide on whether research peptides are legal in the UK. It is, however, a useful illustration of how differently the human-use pharmaceutical-supply chain and the research-reagent supply chain are regulated.
Velox Peptides does not sell tirzepatide, semaglutide, or any FDA-approved medicine in compounded or any other form. Every compound Velox stocks is supplied as an HPLC-verified in vitro research reagent only. Not a medicine. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- U.S. Food and Drug Administration. Empower Clinic Services, LLC dba Empower Pharmacy – 738238 – 09/18/2026. Warning Letter. fda.gov
- BioSpace. FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’. September 2026. biospace.com
- Houston Chronicle. Houston's Empower Pharmacy has repeat quality issues, FDA inspections show. September 2026. houstonchronicle.com
- LumaLex Law. Empower, The B Vitamin, And The Word “Pretextual”. 24 September 2026. lumalexlaw.com
- Buchanan Ingersoll & Rooney PC. FDA Warning Letter to Empower Pharmacy and What It Means for 503A Compounding Pharmacies. September 2026. bipc.com
- American Med Spa Association. FDA Warning Letter Signals Increased Scrutiny of the Medical Necessity Exception for Compounded GLP-1s. September 2026. americanmedspa.org
Frequently Asked Questions
What did the FDA say to Empower Pharmacy on 18 September 2026?
The FDA issued a warning letter to Empower Clinic Services, LLC (dba Empower Pharmacy) of Houston, Texas, citing two separate problems: insanitary conditions at a sterile-compounding facility that could result in products contaminated with filth, and compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin formulations the agency says are essentially copies of FDA-approved drugs, produced in volumes suggesting the added ingredient is a pretextual difference rather than a genuine, patient-specific one.
What does "pretextual" mean in this context?
Section 503A exempts qualifying compounded drugs from FDA premarket approval, but only if the pharmacy does not regularly compound drugs that are essentially copies of a commercially available FDA-approved product. A prescriber can document that a compounded version produces a clinically significant difference for a specific patient. FDA's letter says Empower's records show boilerplate, repeated significant-difference language across many patients rather than individualised medical judgment — evidence, in the agency's view, that the stated difference was pretextual, not real.
Is this only about paperwork, or were there also sterility concerns?
Both. Separately from the pretextual-copy finding, FDA investigators found sterile products at Empower's facility were prepared, packed, or held under insanitary conditions that could result in contamination with filth or products rendered injurious to health, alongside cited deficiencies in equipment maintenance, microbial-contamination controls, quality-unit oversight, environmental monitoring, and written production records. Reporting on the letter notes it is the fourth Empower has received in recent years over facility conditions.
What happens next for Empower and other compounding pharmacies?
Empower has a limited window to respond with corrective action; no seizure, injunction, or referral had been announced as of publication. Legal commentary published in the days after the letter frames it as a signal to the wider 503A compounding industry that adding a low-cost ingredient such as a B-vitamin will not, by itself, satisfy the "significant difference" test if production volume and documentation suggest the addition is not genuinely patient-specific.
Does this affect UK research-reagent supply or Velox Peptides?
No. This is a US enforcement action against a licensed US pharmacy compounding FDA-approved drugs for human patients under Section 503A — a framework that does not exist in UK law and does not apply to Velox Peptides. Velox does not sell tirzepatide or semaglutide in any form. It supplies retatrutide, an investigational compound with no FDA-approved reference product to be a copy of, strictly as an HPLC-verified in vitro research reagent, with no dosing or human-use claims. Order for research →